NASDAQ: INDP - Indaptus Therapeutics, Inc.

半年間の収益性: -61.3%
セクタ: Healthcare

プロモーションスケジュール Indaptus Therapeutics, Inc.


会社について

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc.

さらに詳しく
is headquartered in New York, New York.

IPO date 2015-08-04
ISIN US45339J1051
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://indaptusrx.com
Цена ао 2.8
1日あたりの価格変動: -1.66% (0.85)
週ごとの価格変動: -10.88% (0.938)
月ごとの料金変更: -18.84% (1.03)
3ヶ月間の価格変動: -35.7% (1.3)
半年間の価格変動: -61.3% (2.16)
年間の価格変動: -52.51% (1.76)
3年間の価格推移: -85.1% (5.61)
5年間の価格推移: +70.59% (0.49)
10年間の価格推移: 0% (0.8359)
年初からの価格変動: -16.41% (1)

過小評価

名前 意味 学年
P/S 0 0
P/BV 1.32 9
P/E 0 0
EV/EBITDA -0.1694 0
合計: 3.63

効率

名前 意味 学年
ROA, % -103.35 0
ROE, % -127.71 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0107 10
合計: 9.8

成長の衝動

名前 意味 学年
収益性 Revenue, % 0 0
収益性 Ebitda, % -51.97 0
収益性 EPS, % -98.37 0
合計: 0



スーパーバイザー 役職 支払い 生年
Mr. Jeffrey A. Meckler CEO & Director 867.03k 1967 (58 年)
Mr. Walt Addison Linscott Esq. Chief Operating Officer 716.35k 1961 (64 年)
Dr. Michael J. Newman Ph.D. Founder, Chief Scientific Officer & Director 659.99k 1956 (69 年)
Mr. Nir Sassi CFO, Secretary & Treasurer 378.47k 1976 (49 年)
Dr. Roger J. Waltzman M.B.A., M.D. Chief Medical Officer N/A 1968 (57 年)

住所: United States, New York. NY, Three Columbus Circle - Googleマップで開く, Yandexマップを開く
Webサイト: https://indaptusrx.com